logo
Share SHARE
FONT-SIZE Plus   Neg

Cell Therapeutics Says UW's Neuro-Oncology Program Begins Patient Enrolment

Cell Therapeutics, Inc. (CTIC) on Tuesday said the University of Washington's School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX, CT-2103) and radiation therapy, or RT, to the combination of temozolomide, or TMZ, and RT for patients with newly-diagnosed glioblastoma multiforme.

The study objective is to determine whether paclitaxel poliglumex and RT are likely to improve progression-free survival and overall survival compared to TMZ and RT. It will also evaluate neuro-cognitive function and toxicities of these therapies.

Glioblastoma multiforme or GBM is a poor-prognosis high-grade malignant brain tumor with an active gene called MGMT, which substantially decreases the effectiveness of standard therapy with TMZ.

This study is a multicenter trial initiated and led by the Neuro-Oncology department of the Brown University Oncology Research Group in Providence, Rhode Island. The first patient at UW recently has been enrolled.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Electronics retailer Best Buy Co. Inc. (BBY), has announced it will retail Apple Watch in its store from next month, making it the first retailer besides Apple Stores to offer the smartwatch that was launched three months ago. Initially, Best Buy will start selling the smartwatch in over 100 stores... Here is a quick summary of the earnings reported after the bell on Jul 27. 1.Del Taco Restaurants, Inc. (TACO, TACOW) Q2 Net income was $4.6 million compared to net loss of $0.1 million a year ago. Q2 Total revenue was $97.6 million, an increase of 7.0% compared to $91.2 million a year ago. *** 2.Plantronics,... Semiconductor packaging company Amkor Technology Inc. (AMKR), Monday reported a plunge in profit for the second quarter, as revenues declined and margins narrowed. The bottom line was also impacted by a debt extinguishment charge. Shares of the company fell about 14 percent in extended hours after...
comments powered by Disqus
Follow RTT